Keywords: Fostamatinib, Rheumatoid arthritis, AstraZeneca, Efficacy

AstraZeneca's fostamatinib safe, but not effective, in RA patients unresponsive to biologic agents

Article | 31 January 2011

Print This

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in